Emily Kaiser Maharjan

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

The historic Eye Institute rings in 60 years of leadership in eye care research, education and clinical practice.

Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

Ted Leng, MD, discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Jill Hopkins, MD, discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular edema.

At the 2021 American Academy of Ophthalmology annual meeting, Penny Asbell, MD, FACS, MBA, discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

First annual Geographic Atrophy Awareness Week, hosted by Prevent Blindness, will be December 6-12, 2021.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Results from our recent poll regarding AAO 2021 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in-person.

A poll for retina specialists regarding their attendance at the 2021 American Academy of Ophthalmology Meeting in New Orleans, Louisiana. This poll is now closed.

Luminopia One is one of few digital therapeutics to receive FDA approval via the de novo pathway, and it is the first for amblyopia, and for a neuro-visual disorder in general.

The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

Results from our recent poll about ASRS 2021 meeting attendance shows that ophthalmologists are ready to participate in events, both in-person and online.

The EIDON Ultra-Widefield Lens module from iCare USA has received 510(k) approval from the FDA for distribution in the US.

Results from our recent poll about meeting attendance preferences show an inclination toward flexibility.

In the final installment of his COVID-19 interview series, Dr. Breazzano discusses the positive lessons he's learned during the crisis.

The Association for Research in Vision and Ophthalmology recognizes their latest cohort to complete the Women Leadership Development Program.

The white cane receives assistive updates to guide visually impaired users to destinations, making indoor navigation in unfamiliar locations easier and safer.

Dr. Breazzano discusses the professional challenges and personal effects he faced during the beginning of the COVID-19 pandemic.

A poll for retina specialists regarding their preference on attending specialty conferences and meetings. This poll is closed.

Dr. Breazzano discusses how clinicians can learn from the COVID-19 pandemic and prepare for future crises.

A synopsis of the findings presented at EURETINA 2021 for ophthalmologists and retina specialists.

Mark Breazzano, MD, discusses his views on the future of telehealth for ophthalmologists and retina specialists.

Mark Breazzano, MD, discusses his research into the decrease in urgent and emergent procedures in ophthalmology, how he's handling it in his practice, and how to make patients more comfortable coming in to receive care.